The University of Wisconsin Carbone Cancer Center has the go-ahead to start clinical trials on a first-in-human cell therapy to treat a common side effect of radiation therapy.
This investigational new drug license, or IND, recently issued by the Food and Drug Administration will allow UW oncologists to study a new cell therapy to treat radiotherapy-induced xerostomia, also called dry mouth.
The new IND offers an entirely novel use of personalized cell therapy with the patient’s own interferon-gamma activated marrow stromal cells, according to Jacques Galipeau, MD, associate dean for therapeutics development and director of the UW Program for Advanced Cell Therapy.
Read the full article at: https://www.med.wisc.edu/news-and-events/2020/september/carbone-cancer-center-to-test-dry-mouth-therapy